GC
XFOR icon

Grimes & Company’s X4 Pharmaceuticals XFOR Stock Holding History

Grimes & Company’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-500
Closed -$20.9K – 360
2024
Q1 		$20.9K Hold
500
– – ﹤0.01% 342
2023
Q4 		$12.6K Hold
500
– – ﹤0.01% 330
2023
Q3 		$16.4K Hold
500
– – ﹤0.01% 305
2023
Q2 		$29.1K Buy
+500
New +$25.7K ﹤0.01% 303

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Grimes & Company's XFOR Position: Q2 2024 in Review

Grimes & Company sold out of X4 Pharmaceuticals (XFOR) in Q2 2024, closing a stake of 500 shares — an estimated $20.9K sold.

Grimes & Company first reported a position in XFOR in Q2 2023 and held it in 4 quarters. The position peaked at $29.1K in Q2 2023. 98 funds tracked by Wall St. Rank hold XFOR as of Q2 2024.

  • Grimes & Company reported no remaining X4 Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Grimes & Company sold 500 X4 Pharmaceuticals shares in Q2 2024, an estimated $20.9K.
  • Grimes & Company first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 4 quarters.
  • Grimes & Company's X4 Pharmaceuticals position peaked at $29.1K in Q2 2023.
  • 98 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2024.

Based on Grimes & Company's 13F filing for Q2 2024, filed 22 Jul 2024.